drugset / Trial / NCT01081964

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

NCT01081964

Phase 2 Terminated 48 enrolled IASO Pharma Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.

Timeline

Start
2010-03
Primary completion
2012-04
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Levofloxacin Small molecule 500 mg Oral
Subject Zabofloxacin Small molecule 400 mg Oral

Indications

No indication recorded.